A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
about
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A phase I open-label dose-esca ...... sing breast or gastric cancer.
@en
type
label
A phase I open-label dose-esca ...... sing breast or gastric cancer.
@en
prefLabel
A phase I open-label dose-esca ...... sing breast or gastric cancer.
@en
P2093
P2860
P50
P1433
P1476
A phase I open-label dose-esca ...... sing breast or gastric cancer.
@en
P2093
Abdelkader Seroutou
Alex Morozov
Angela Zubel
Chia-Chi Lin
Dejan Juric
Donna M Graham
Ezra Cohen
José Baselga
Kerry Lynn Reynolds
Maria Alsina
P2860
P2888
P356
10.1186/S12885-017-3641-6
P407
P577
2017-09-12T00:00:00Z
P6179
1091592092